- Home
- REPL vs BCX Comparison
REPL vs BCX Comparison
Compare REPL & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- BCX
- Stock Information
- Founded
- REPL 2015
- BCX 2011
- Country
- REPL United States
- BCX United States
- Employees
- REPL N/A
- BCX N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- BCX Finance/Investors Services
- Sector
- REPL Health Care
- BCX Finance
- Exchange
- REPL Nasdaq
- BCX Nasdaq
- Market Cap
- REPL 578.4M
- BCX 674.0M
- IPO Year
- REPL 2018
- BCX N/A
- Fundamental
- Price
- REPL $7.71
- BCX $9.13
- Analyst Decision
- REPL Strong Buy
- BCX
- Analyst Count
- REPL 6
- BCX 0
- Target Price
- REPL $20.00
- BCX N/A
- AVG Volume (30 Days)
- REPL 1.1M
- BCX 370.6K
- Earning Date
- REPL 05-19-2025
- BCX 01-01-0001
- Dividend Yield
- REPL N/A
- BCX 6.99%
- EPS Growth
- REPL N/A
- BCX N/A
- EPS
- REPL N/A
- BCX N/A
- Revenue
- REPL N/A
- BCX N/A
- Revenue This Year
- REPL $31.16
- BCX N/A
- Revenue Next Year
- REPL N/A
- BCX N/A
- P/E Ratio
- REPL N/A
- BCX N/A
- Revenue Growth
- REPL N/A
- BCX N/A
- 52 Week Low
- REPL $4.92
- BCX $8.25
- 52 Week High
- REPL $17.00
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- REPL 39.21
- BCX 58.29
- Support Level
- REPL $6.93
- BCX $8.95
- Resistance Level
- REPL $10.30
- BCX $9.10
- Average True Range (ATR)
- REPL 0.73
- BCX 0.11
- MACD
- REPL -0.07
- BCX 0.03
- Stochastic Oscillator
- REPL 23.15
- BCX 95.10
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.